dong_1996
dong_1996
dong_1996
28875–28883, 1996
© 1996 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A.
Plasma membrane P-glycoprotein is known as an ATP- mdr2), but only mdr1 genes encode Pgp that is involved in the
dependent drug efflux pump that confers multidrug re- MDR phenotype (1, 2). Pgp has been described as an ATP-de-
sistance to tumor cells. None of the reported purification pendent drug efflux pump that extrudes drugs out of cells and
procedures worked properly for our P-glycoprotein-over- thus confers cell resistance by lowering intracellular drug con-
producing cell lines, i.e. murine lymphoid leukemia P388/ centration (1). However, the mechanism by which this phenom-
ADR25, rat hepatoma AS30-D/COL10, and human lympho- enon occurs remains unclear and is of particular interest be-
blastic leukemia CEM/VLB5 cells. We have thus developed a cause of its broad specificity for structurally dissimilar
general procedure for efficient purification of P-glycopro-
substrates. Two models have been proposed (3). The first one
tein by combining solubilization with sodium dodecyl sul-
states that Pgp would be organized as a hydrophilic pore
fate and chromatography on ceramic hydroxyapatite. This
through which the drug is effluxed. In the second model, Pgp
%
Octylglucoside (1.4%) 11 39
Dodecyl maltoside (0.4%) 16 47
Chaps (1%) 24 61
Zwittergent 3–12 (0.4%) 14 51
Sodium deoxycholate (2%) 30 —a
SDS (2%) 93 NDb
a
Not soluble in the presence of 1 M NaCl.
b
Not determined.